RT Book, Section
A1 Hogg, Kerstin
A1 Weitz, Jeffrey I.
A2 Brunton, Laurence L.
A2 Hilal-Dandan, Randa
A2 Knollmann, Björn C.
SR Print(0)
ID 1162539182
T1 Blood Coagulation and Anticoagulant, Fibrinolytic, and Antiplatelet Drugs
T2 Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 13e
YR 2017
FD 2017
PB McGraw-Hill Education
PP New York, NY
SN 9781259584732
LK accessbiomedicalscience.mhmedical.com/content.aspx?aid=1162539182
RD 2024/04/19
AB Blood  must  remain  fluid  within  the  vasculature  and  yet  clot  quickly  when  exposed  to  subendothelial  surfaces  at  sites  of  vascular  injury.  Under  normal  circumstances,  a  delicate  balance  between  coagulation  and  fibrinolysis  prevents  both  thrombosis  and  hemorrhage.  Alteration  of  this  balance  in  favor  of  coagulation  results  in  thrombosis.  Thrombi,  composed  of  platelet  aggregates,  fibrin,  and  trapped  red  blood  cells,  can  form  in  arteries  or  veins.  Antithrombotic  drugs  used  to  treat  thrombosis  include  antiplatelet  drugs,  which  inhibit  platelet  activation  or  aggregation;  anticoagulants,  which  attenuate  fibrin  formation;  and  fibrinolytic  agents,  which  degrade  fibrin.  All  antithrombotic  drugs  increase  the  risk  of  bleeding.